Commissioning considerations for the Bravos high-dose-rate afterloader: Towards improving treatment delivery accuracy

IF 1.7 4区 医学 Q4 ONCOLOGY
Gil'ad N. Cohen , Xiuxiu He , Michael Trager , Maria F. Chan , Jeonghoon Park , Antonio L. Damato , David Aramburu Nunez
{"title":"Commissioning considerations for the Bravos high-dose-rate afterloader: Towards improving treatment delivery accuracy","authors":"Gil'ad N. Cohen ,&nbsp;Xiuxiu He ,&nbsp;Michael Trager ,&nbsp;Maria F. Chan ,&nbsp;Jeonghoon Park ,&nbsp;Antonio L. Damato ,&nbsp;David Aramburu Nunez","doi":"10.1016/j.brachy.2024.06.010","DOIUrl":null,"url":null,"abstract":"<div><h3>BACKGROUND And PURPOSE</h3><div>The upgrade of major equipment can be disruptive to clinical operations and introduce risk as policy and procedures need to adapt to new technical possibilities and constraints. We describe here the transition from GammaMed<em>Plus</em>-iX to Bravos in a busy brachytherapy clinic, involving four afterloaders across two sites.</div></div><div><h3>MATERIAL And METHODS</h3><div>Our clinic employs three high-dose-rate remote afterloaders in four dedicated treatment vaults at the main site and a fourth afterloader at a regional location. Of more than 600 new HDR treatment plans performed annually, most are planned and treated intraoperatively. Most treatments are for prostate cancer, followed by GYN, intraoperative brachytherapy, GI, and other sites. Applicators used include vendor-provided applicators as well as third party applicators and in-house 3D-printed devices to provide interstitial, intracavitary, intraluminal, and surface treatments. All applicators were commissioned according to recommended guidelines. The choice of tolerances and the design of new procedures were informed by current guidelines and leveraged new HDR afterloader functionalities. A review of clinical operations in the 4 months postupgrade was conducted to evaluate the feasibility of new tolerances and the effectiveness of new procedures.</div></div><div><h3>RESULTS</h3><div>The procedures outlined improved and standardized afterloader QA and treatment protocols with clear actionable steps for staff to follow to ensure treatments are delivered as planned. Re-commissioning of applicators yielded results similar to those previously reported by other investigators. A review of initial treatment data revealed that in one case, due to the implementation of tight tolerances, obstruction near the tip of the channel was detected and corrected prior to treatment. It confirms that the implementation of the tolerances adopted is feasible and effective in flagging treatment deviations.</div></div><div><h3>CONCLUSION</h3><div>Enhanced procedures and QA processes were implemented successfully. We established clear actionable steps to follow by staff to ensure that treatments are delivered accurately.</div></div>","PeriodicalId":55334,"journal":{"name":"Brachytherapy","volume":"23 6","pages":"Pages 705-711"},"PeriodicalIF":1.7000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Brachytherapy","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1538472124001119","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

BACKGROUND And PURPOSE

The upgrade of major equipment can be disruptive to clinical operations and introduce risk as policy and procedures need to adapt to new technical possibilities and constraints. We describe here the transition from GammaMedPlus-iX to Bravos in a busy brachytherapy clinic, involving four afterloaders across two sites.

MATERIAL And METHODS

Our clinic employs three high-dose-rate remote afterloaders in four dedicated treatment vaults at the main site and a fourth afterloader at a regional location. Of more than 600 new HDR treatment plans performed annually, most are planned and treated intraoperatively. Most treatments are for prostate cancer, followed by GYN, intraoperative brachytherapy, GI, and other sites. Applicators used include vendor-provided applicators as well as third party applicators and in-house 3D-printed devices to provide interstitial, intracavitary, intraluminal, and surface treatments. All applicators were commissioned according to recommended guidelines. The choice of tolerances and the design of new procedures were informed by current guidelines and leveraged new HDR afterloader functionalities. A review of clinical operations in the 4 months postupgrade was conducted to evaluate the feasibility of new tolerances and the effectiveness of new procedures.

RESULTS

The procedures outlined improved and standardized afterloader QA and treatment protocols with clear actionable steps for staff to follow to ensure treatments are delivered as planned. Re-commissioning of applicators yielded results similar to those previously reported by other investigators. A review of initial treatment data revealed that in one case, due to the implementation of tight tolerances, obstruction near the tip of the channel was detected and corrected prior to treatment. It confirms that the implementation of the tolerances adopted is feasible and effective in flagging treatment deviations.

CONCLUSION

Enhanced procedures and QA processes were implemented successfully. We established clear actionable steps to follow by staff to ensure that treatments are delivered accurately.
Bravos 高剂量率后装载器的调试注意事项:提高治疗精确度。
背景和目的:由于政策和程序需要适应新的技术可能性和限制,因此主要设备的升级可能会扰乱临床操作并带来风险。我们在此介绍一家繁忙的近距离放射治疗诊所从 GammaMedPlus-iX 到 Bravos 的过渡过程,其中涉及两个地点的四台后装载器:材料: 我们诊所在主站的四个专用治疗库中使用了三台高剂量率远程后装机,在一个区域地点使用了第四台后装机。在每年进行的 600 多例新的 HDR 治疗计划中,大多数都是在术中计划和治疗的。大多数治疗是针对前列腺癌,其次是妇科、术中近距离放射治疗、消化道和其他部位。使用的涂抹器包括供应商提供的涂抹器、第三方涂抹器和内部 3D 打印设备,以提供间质、腔内、腔内和表面治疗。所有涂抹器都是根据推荐准则调试的。公差的选择和新程序的设计均参考了现行指南,并充分利用了新的 HDR 后装载器功能。对升级后 4 个月的临床操作进行了回顾,以评估新公差的可行性和新程序的有效性:结果:程序概述了经过改进和标准化的后装载器质量保证和治疗方案,为员工提供了明确的可操作步骤,以确保按计划进行治疗。重新调试施药器的结果与其他调查人员之前报告的结果相似。对初始处理数据的审查显示,在一个案例中,由于执行了严格的公差,在处理前发现并纠正了通道顶端附近的阻塞。这证实了所采取的公差措施是可行的,并能有效地发现治疗偏差:我们成功实施了强化程序和质量保证流程。我们为员工制定了明确的可操作步骤,以确保治疗的准确性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Brachytherapy
Brachytherapy 医学-核医学
CiteScore
3.40
自引率
21.10%
发文量
119
审稿时长
9.1 weeks
期刊介绍: Brachytherapy is an international and multidisciplinary journal that publishes original peer-reviewed articles and selected reviews on the techniques and clinical applications of interstitial and intracavitary radiation in the management of cancers. Laboratory and experimental research relevant to clinical practice is also included. Related disciplines include medical physics, medical oncology, and radiation oncology and radiology. Brachytherapy publishes technical advances, original articles, reviews, and point/counterpoint on controversial issues. Original articles that address any aspect of brachytherapy are invited. Letters to the Editor-in-Chief are encouraged.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信